Surmodics (Surmodics) Interest Expense

: $-3.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Surmodics's interest expense for the three months ended in Dec. 2023 was $ -0.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Surmodics's Operating Income for the three months ended in Dec. 2023 was $ -0.3 Mil. Surmodics's Interest Expense for the three months ended in Dec. 2023 was $ -0.9 Mil. Surmodics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Surmodics Interest Expense Historical Data

The historical data trend for Surmodics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Expense

Get a 7-Day Free Trial

-0.15

-0.13

-0.31

-0.60

-3.49

Surmodics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.83	-0.88	-0.88	-0.90	-0.90

Surmodics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.6 Mil.

Surmodics (NAS:SRDX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Surmodics's Interest Expense for the three months ended in Dec. 2023 was $-0.9 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-0.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $32.9 Mil.

Surmodics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Surmodics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Surmodics (Surmodics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SU6:Germany

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Executives

Jose H Bedoya	director
David Dantzker	other: See Explanation of Responses	80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr	director
Gary R Maharaj	director, officer: President & CEO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich	officer: VP, Corp Dev & Strat Planning	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson	officer: General Manager
John D. Manders	officer: Corporate Controller	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber	officer: Sr. VP of Legal, GC and Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana	officer: VP, Clinical Affairs	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine	director	1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides	officer: Senior VP and CMO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton	officer: VP of Research and Development	6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight	director	9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips	officer: Dep. Gen. Counsel & Corp. Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens	officer: General Manager - IVD	9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344